Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nephoxil Phase IV in ESRD
NCT03256838Phase 4Completed
- Sponsor
- Panion & BF Biotech Inc.
- Start
- Apr 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ferric citrate in hyperphosphatemia, sponsored by Panion & BF Biotech Inc. Primary endpoints: Number of subjects with treatment-emergent adverse events at 13 months and Percentage of subjects with treatment-emergent adverse events at 13 months. Started Apr 2017; status: completed.
02
Drugs
ferric citrate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT03256838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03256838.